Indaptus Therapeutics/$INDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Indaptus Therapeutics
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Ticker
$INDP
Sector
Primary listing
Employees
5
Headquarters
Website
INDP Metrics
BasicAdvanced
$421m
-
-$5.27
1.39
-
Price and volume
Market cap
$421m
Beta
1.39
52-week high
$13.40
52-week low
$0.92
Average daily volume
2m
Financial strength
Current ratio
2.337
Quick ratio
1.605
Profitability
Management effectiveness
Return on assets (TTM)
-286.81%
Return on equity (TTM)
-931.79%
Valuation
Price to book
337.6
Price to tangible book (TTM)
337.6
Price to free cash flow (TTM)
-0.794
Free cash flow yield (TTM)
-126.02%
Free cash flow per share (TTM)
-4.688
Growth
Earnings per share change (TTM)
-87.19%
3-year earnings per share growth (CAGR)
-53.19%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs